2017 Fiscal Year Final Research Report
Development of oral cancer treatment by hyperthermia generated with contrast agent Resovist and Cetuximab
| Project/Area Number |
26463053
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
來生 知 横浜市立大学, 医学部, 准教授 (30545059)
藤内 祝 横浜市立大学, 医学研究科, 教授 (50172127)
光藤 健司 横浜市立大学, 医学部, 准教授 (70303641)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | 口腔癌 / ハイパーサーミア / セツキシマブ |
|---|
| Outline of Final Research Achievements |
The purpose of this study is the development of a new treatment for oral cancer indicating the resistance for the anticancer effect of cetuximab by using hyperthermia generated with contrast agent Resovist in an alternating magnetic field(AMF) and Cetuximab.We found that the expression of EGFR in human oral squamous cell carcinoma cells increased by thermal stimulation.Therefore, we thought that the sensitivity of Cetuximab-resistant human oral squamous cell carcinoma cells for cetuximab can be activated by thermal stimulation-induced high expression of EGFR.As a result of the study using mouse models based on this speculation, the anti-cancer effect were observed in the group treated with combination of cetuximab and hyperthermia generated with contrast agent Resovist in AMF.
|
| Free Research Field |
口腔外科学
|
